Trial 2N-23-3


A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Other
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Robert Hsu, M.D.
Other Trial Staff:  Sreebharathy Venkatesh, D.M., Sana Mutalib, Coordinator, Anisa Sandin, Coordinator, Thomas Won, Coordinator, Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.